RedHill Biopharma posts corporate presentation on Talicia commercialization and GI-focused pipeline

RedHill Biopharma Ltd. Sponsored ADR

RedHill Biopharma Ltd. Sponsored ADR

RDHL

0.00
  • RedHill Biopharma highlighted FY 2025 net revenue of USD 7.8 million, cash balance of USD 4.1 million, gross margin of 74.6%.
  • Market cap shown at about USD 5.2 million; ADS count about 5,200,000; stated equity financing capacity of USD 31.7 million.
  • Talicia positioned as the lead commercial product; co-commercialization partnership with Cumberland Pharmaceuticals to drive US sales growth.
  • Pipeline focus includes opaganib in an ongoing Phase 2 combination study with Bayer’s darolutamide in prostate cancer.
  • RHB-102 planned Phase 2 study for GLP-1/GIP-associated GI intolerance; RHB-204 shown as Phase 3-stage for pulmonary NTM disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.